Resolvin D1 mitigates inflammatory response in DSS-induced colitis mice by inhibiting NLRP3 inflammasome activation
10.3969/j.issn.1001-1978.2019.04.027
- Author:
Chen FANG
1
Author Information
1. Dept of Gastroenterology, First Affiliated Hospital, Anhui Medical University, Key Lab of Digestive Diseases of Anhui Province
- Publication Type:Journal Article
- Keywords:
Cytokines;
Dextran sodium sulfate;
Inflammatory bowel disease;
Intestinal mucosa;
NLRP3;
Resolvin D1
- From:
Chinese Pharmacological Bulletin
2019;35(4):580-585
- CountryChina
- Language:Chinese
-
Abstract:
Aim: To investigate the effect of resolvin Dl (RvDl) on DSS-induced mice colitis model and the possible mechanism. Methods: C57BL/6 mice were divided into four groups: normal group, control group, dextran sodium sulfate (DSS) model group, and RvDl group. RvDl was dissolved in physiological saline and intraperitoneally injected into experimental mice on 2nd day, 4th day and 6th day. The disease activity index (DAI), histological index (HI), myeloperoxidase (MPO) were detected using Evans blue test, electron microscopy and cytokine level test. The expression differences of NLRP3, ASC, caspase-1, pro-IL-1 β and other related genes were analyzed. Results: The DAI score, HI score, MPO activity level, and pro-inflammatory cytokine in colon tissue homogenate were significantly raised in DSS group compared with those of the normal group (P < 0. 05). The above indexes of RvDl experimental group were significantly reduced(P < 0. 05). At the same time, the expressions of NPRP3 pathway-related proteins, such as NLRP3, ASC, caspase-1 and pro-IL-1 (3, increased in DSS group(F < 0. 05); the expression of the above proteins decreased after RvDl treatment(P < 0. 05). Conclusions: RvDl can mitigate inflammatory response in DSS-induced colitis mice, which may involve the inhibition of RvDl of the NLRP3 inflammasome signaling pathway.
